ALBUQUERQUE, N.M.--(BUSINESS WIRE)-- In the November issue of the President’s Column, cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) thanked veterans for their contribution to the pilot clinical study of the Company's CyPath® diagnostic assay for the detection of early-stage lung cancer. The November President's Column can be found at www.biomoda.com.
“The success of Biomoda will be directly tied to the selflessness of our veterans who once again stepped forward to help others,” Biomoda President John Cousins wrote in the column. Biomoda expects military veterans at high risk for developing lung cancer to play a key role in the upcoming pivotal study of the lung cancer assay. According to the U.S. Department of Defense, veterans are at least 25% more likely to develop lung cancer and die from the disease.
Cousins also said that the Company is currently enrolling additional patients, who have been diagnosed with a primary lung cancer but have not yet begun treatment, for the positive control cohort in the pilot study. Christiana Care Health Center is enrolling patients for the pilot study, and the Company is in discussion with several other prestigious medical institutions to participate in both the pilot and pivotal studies. “We are on a forward path to securing several collection sites and obtaining the required number of patient samples to complete the pilot study and move into our pivotal study,” Cousins said.
Biomoda’s CyPath® labeling solution for the early detection of cancers binds to cancer cells and fluoresces under specific frequencies of medium light. Biomoda is seeking Food and Drug Administration (FDA) approval of its cytology-based screening technology as a Class III medical device. Pending FDA approval, CyPath® is for investigational use only.
Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, which are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 30, 2010. Forward-looking statements are made as of the date of this press release and are subject to change without notice.
Julie Anne Overton, 505-577-0918
KEYWORDS: United States North America New Mexico
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Hospitals Medical Devices Oncology Radiology FDA General Health